Nuvalent Inc (NUVL) Appoints Michael L. Meyers to its Board

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Michael L. Meyers, M.D., Ph.D., to its Board of Directors. An experienced drug developer and medical oncologist who has contributed to the successful development and commercialization of multiple new therapies for patients with cancer, Dr. Meyers has served as a Senior Clinical Advisor to Nuvalent since 2020.

"We look forward to leveraging Michael's deep expertise in oncology and clinical development as we prepare to enter into later stages of development for our parallel lead programs NVL-520 and NVL-655, while also advancing our newest drug candidate NVL-330 into development," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "Michael's experience in end-to-end drug development and the lessons learned from working with and building small companies lends a unique and valuable perspective to our Board as we continue to mature our portfolio and further build the corporate infrastructure needed to bring our novel therapies to patients with cancer."

Dr. Meyers has established a legacy of industry leadership spanning early-phase development to late-stage life cycle management for both liquid and solid tumors. During his career, he served as the Senior Vice President, Chief Development Officer and Chief Medical Officer at Syndax Pharmaceuticals, Inc., where he led the development of multiple molecules in breast cancer, various immune-oncology indications, acute leukemias, and chronic Graft Versus Host Disease. Before joining Syndax, he held a number of senior R&D roles at Johnson & Johnson, including serving as Vice President, GU Oncology, Compound and Clinical Leader, and Vice President, Oncology Scientific Innovation at Johnson & Johnson's London Innovation Centre. Dr. Meyers has also led the U.S. Oncology Medical Affairs team at Aventis Pharmaceuticals Inc. and worked in oncology clinical development at the Schering-Plough Research Institute. Prior to this, he served on the faculty at Memorial Sloan Kettering Cancer Center, specializing in clinical immunology and melanoma.

"The Nuvalent team has shown itself to be passionate about patients' needs and has clearly demonstrated its commitment to working at the cutting edge of oncology drug development," said Dr. Meyers. "With a growing portfolio of potentially best-in-class molecules addressing validated oncology drivers, I look forward to supporting the Nuvalent team in its mission to translate its deep expertise in chemistry and structure-based drug design into meaningful medicines to address significant medical needs in a number of high impact cancers."

Dr. Meyers received his M.D. and his Ph.D. in Microbiology and Immunology from Albert Einstein College of Medicine in New York. He completed his residency in Internal Medicine at Columbia Presbyterian Medical Center and his fellowship at Memorial Sloan Kettering Cancer Center, where he served as Chief Fellow in Medical Oncology.

Nuvalent is currently enrolling patients in the Phase 1 portion of its ARROS-1 study, a Phase 1/2 clinical trial evaluating its lead candidate NVL-520, a ROS1-selective inhibitor, in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors. The company is also actively dosing patients in the Phase 1 portion of its ALKOVE-1 trial, a Phase 1/2 clinical trial evaluating parallel lead candidate NVL-655, an ALK-selective inhibitor, in patients with advanced ALK-positive NSCLC and other solid tumors. NVL-520 and NVL-655 are designed with the aim to address the clinical challenges of emergent treatment resistance, off-target CNS adverse events, and brain metastases that may limit the use of currently available kinase inhibitors. In addition, Nuvalent recently announced the nomination of a third development candidate NVL-330, a potential best-in-class HER2-selective inhibitor, for patients with HER2 Exon 20 insertion-positive cancers.

You May Also Be Interested In

• Jefferies Starts Nuvalent (NUVL) at Buy, 'Precisely Targeted Oncology Aiming for Firstline Treatment'
• New York Community Bancorp (NYCB) Appoints Craig Gifford as CFO
• CN (CNI) Brings Back Remi G. Lalonde as Chief Commercial Officer